Acta Med. 2003, 46: 163-170
https://doi.org/10.14712/18059694.2019.27
A Study of Potential Toxic Effects After Repeated 10-Week Administration of a New Iron Chelator – Salicylaldehyde Isonicotinoyl Hydrazone (SIH) to Rabbits
References
1. Biochem Pharmacol 1983; 34:298–302.
E, Vitolo M, Webb J. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.
2. Transplantation 1987; 44:195–201.
< A, Jarrell BE, Hirsch S, Carabasi RA, Cressman MD, Green P. Use of the isolated perfused kidney model to assess the acute pharmacologic effects of cyclosporine and its vehicle, cremophor EL. https://doi.org/10.1097/00007890-198708000-00005>
3. Dorr TR. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother 1994; 28(suppl 5):S11–S14.
4. Coord Chem Rev 1999; 184:291–310.
< G, Crisponi G. Iron chelating agents in clinical practice. https://doi.org/10.1016/S0010-8545(99)00056-9>
5. Ganong WF. Review of medical physiology. 19th edition. New York: Lange Medical Books, 1997:542.
6. J Pharmacol Exper Therap 1997; 281:1127–35.
J, Domb A, Teomim D. The treatment of animal models of malaria with iron chelators by use of a novel polymeric device for slow drug release.
7. Hardman JG, Limbird LE, eds. Goodman&Gilman’s The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001:698.
8. Bioch Bioph Acta 1999; 1426:475–82.
< M, Santos NCF, Yan J, Andrews M, Schulman HM, Ponka P. EPR spin trapping and 2–deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on. OH formation by the Fenton reaction. https://doi.org/10.1016/S0304-4165(98)00167-6>
9. Cardiovasc Res 2000; 47:529–36.
< M, Ponka P, Byczko Z. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H2O2 injury in adult cardiomyocytes. https://doi.org/10.1016/S0008-6363(00)00088-2>
10. Biomarkers Environ 2001; 4(suppl 1):70–2.
I, Šimůnek T, Geršl V et al. Biochemical and haematological changes following reapeated pyridoxal isonicotinoyl hydrazone administration in rabbits.
11. Kraus AL, Weisbroth SH, Flatt RE, Brewer N. Biology and diseases of rabbits. In: Fox JG, Cohen BJ, Loew FM, eds. Laboratory animal medicine. Orlando: Academic Press, 1984:212–3.
12. Mol Asp Med 2001; 22:1–87
< PT, Heiskala M, Peterson PA, Yang Y. The roles of iron in health and disease. https://doi.org/10.1016/S0098-2997(00)00006-6>
13. Bioch Biophys Acta 1979; 586:278–97.
< P, Borová J, Neuwirt J, Fuchs O, Nečas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. https://doi.org/10.1016/0304-4165(79)90100-4>
14. Cardiovasc Res 1996; 31:873–81.
< MP, Black M, Cobbe SM. Comparison of in vivo and in vitro haemodynamic function in experimental heart failure: use of echocardiography. https://doi.org/10.1016/S0008-6363(96)00051-X>
15. Racek J et al. Klinická biochemie. 1. ed. Praha: Galen, 1999:80.
16. Am J Hematol 1998; 58:299–305.
< DR, Ponka P. Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. https://doi.org/10.1002/(SICI)1096-8652(199808)58:4<299::AID-AJH9>3.0.CO;2-L>
17. J Lab Clin Med 1998; 131:306–14.
< DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease. https://doi.org/10.1016/S0022-2143(98)90180-9>
18. Redox Report 1996; 1:373–8.
< HM, Hermes-Lima M, Wang E-M, Ponka P. In vitro antioxidant properties of the iron chelator pyridoxal isonicotinoyl hydrazone and some of its analogs. https://doi.org/10.1080/13510002.1995.11747014>
19. Acta Med (Hradec Králové) 2001; 44:64.
T, Klimtová I, Geršl V et al. Effects of 10–week pyridoxal isonicotinoyl hydrazone administration on selected organ systems in rabbits (abstract).
20. Biomarkers Environ 2001; 4(suppl 1):70–2.
T, Klimtová I, Hrdina R et al. The effects of repeated administration of pyridoxal isonicotinoyl hydrazone on cardiovascular system in rabbits.
21. Drug Chem Toxicol 1991; 14:395–403.
< N, Nakornchai S, Weerapradist W. Toxicological study of pyridoxal isonicotinoyl hydrazone: acute and subchronic toxicity. https://doi.org/10.3109/01480549109011641>
22. Clin Nephrol 1986; 25(suppl 1):S40–2.
G, Hermle M, Brunner FP. Acutely impaired renal function during intravenous administration of cyclosporine A: a cremophore side-effects.
23. Neph 1991; 57:470–6.
< JA, Yatscoff RW, Lukowski MP, Copeland KR, Jeffery JR, Murphy GF. Chronic cislosporin nephrotoxicity: A rabbit model. https://doi.org/10.1159/000186351>
24. J Lab Clin Med 1996; 127:574–82.
< A, Loyevsky M, Ponka P, Cabantchik ZI. Mode of action of iron (III) chelators as antimalarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. https://doi.org/10.1016/S0022-2143(96)90148-1>
25. Mol Pharmacol 1997; 51:842–52.
< G, Glickstein H, Breuer W et al. Chelation and mobilization of cellular iron by different classes of chelators. https://doi.org/10.1124/mol.51.5.842>